Nivolumab & Melanoma (cutaneous)

Regulatory status:

In the context of Nivolumab & Melanoma (cutaneous), Nivolumab is approved by both FDA and EMA for Melanoma (cutaneous), in advanced (unresectable/metastatic) and adjuvant settings, though exact labeled uses differ slightly between regions (1, 2).

Clinical data

In the real world, the safety profiles of nivolumab at doses of 240 mg every two weeks and 480 mg every four weeks were found to be similar. Both dosing regimens were comparable to the well-documented safety of weight-based dosing at 3 mg/kg every two weeks. This further supports their approval and…